Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B Trial - PubMed
4 hours ago
- #multiple myeloma
- #belantamab mafodotin
- #clinical trial
- The DREAMM-6 Arm B trial evaluated belantamab mafodotin combined with bortezomib/dexamethasone (BVd) in relapsed/refractory multiple myeloma (RRMM).
- Patients received varying doses of belantamab mafodotin (1.9, 2.5, or 3.4 mg/kg) with different schedules (Q3W, Q6W, or split doses).
- No dose-limiting toxicities (DLTs) were observed during dose escalation.
- The most common Grade 3/4 adverse event (AE) was keratopathy (53%).
- Ocular events were reported in 93% of patients, with 77% being Grade 3/4.
- 26% of patients experienced serious AEs (SAEs), with 3 out of 7 fatal SAEs being treatment-related.
- The overall response rate (ORR) was 70% (95% CI: 60.5, 78.6).
- Higher initial drug exposures correlated with better response rates but also more ocular events.
- The study concluded that BVd has manageable safety and efficacy, supporting the 2.5 mg/kg Q3W dose.